Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335335 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
A Phase 3 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00335335 is a Phase 3 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 89 participants.
The verdict
NCT00335335, a Phase 3 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body. VISIPAQUE™ will be given through a vein in the arm before having the CTA scan of the heart arteries. The pictures it produces of the heart and its blood vessels will be reviewed and compared to those obtained during the catheter-based coronary angiography to see if the CTA shows the same blockages.
Interventions
- DRUG iodixanol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335335
The ClinicalTrials.gov registry entry for NCT00335335 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iodixanol is the first listed.
NCT00335335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335335 about?
NCT00335335 is a clinical study titled "Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart". CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body. VISIPAQUE™ will be given through a vein in the arm before having the CTA scan of the heart a...
What is the current status of trial NCT00335335?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2006-05. Estimated completion is 2006-12-02.
What interventions are being tested in trial NCT00335335?
The interventions under investigation include: iodixanol (DRUG).
Who is sponsoring clinical trial NCT00335335?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.